Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

MoBIE: New user-friendly, freely available tool for sharing large imaging data sets

High-resolution microscopy techniques, for example electron microscopy or super-resolution microscopy, produce huge amounts of data.

24 Feb 2023

Insilico Medicine: IND application for first generative AI-designed drug for COVID-19 approved

Insilico Medicine, a clinical-stage biotech company powered by generative AI, today announces that China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ISM3312, an orally available 3CLpro inhibitor generated and designed with the support of Insilico's proprietary generative chemistry platform Chemistry42 for the treatment of COVID-19.

24 Feb 2023

Prototype treatment shows great potential in neutralizing snake toxins from multiple species

Prototype treatment for snake bite envenoming proves effective against the venom of African and Asian elapid snakes, such as some cobra, mamba, and krait species, new research shows.

24 Feb 2023

Mount Sinai researchers illuminate the role of DNA methylation in Alzheimer's disease

Mount Sinai researchers have published a study in Alzheimer's & Dementia: The Journal of the Alzheimer's Association that sheds new light on the role of DNA methylation in Alzheimer's disease (AD).

23 Feb 2023

"Poisoned" form of a protein could set off events that encourage cancer growth

Scientists at Scripps Research, with collaborators in Japan, have discovered how a "poisoned" form of a protein could set off a cascade of events that encourage the growth of some cancers.

17 Feb 2023

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform.

From Inventia Life Science 16 Feb 2023

An innovative strategy for on-demand contraception for men

An experimental contraceptive drug developed by Weill Cornell Medicine investigators temporarily stops sperm in their tracks and prevents pregnancies in preclinical models. The study, published in Nature Communications on Feb. 14, demonstrates that an on-demand male contraceptive is possible.

16 Feb 2023

New family of pharmaceutical compounds that target RNA

In Jennifer Hines’ lab, a group of graduate and undergraduate chemistry students recently discovered a new family of compounds that can target RNA and interfere with its function. In the future, RNA-targeted treatments to treat cancer and metabolic diseases, together with bacterial and viral infections, could be developed using the chemical scaffold found in this research.

15 Feb 2023

Gaining insights into human disease biology through CRISPR platforms

In this interview, we speak with Laralynne Przybyla about how she is utilizing CRISPR platforms to understand human disease biology in greater detail.

From Society for Laboratory Automation and Screening (SLAS) 7 Feb 2023

New chemical reaction could transform drug production

Pharmaceutical synthesis is often quite complex; simplifications are needed to speed up the initial phase of drug development and lower the cost of generic production.

3 Feb 2023

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

The January 2023 issue of SLAS Discovery contains a collection of four full-length articles and one technical brief covering cancer research, high-throughput screening (HTS) assay development and other drug discovery exploration.

31 Jan 2023

bit.bio partners with Automata to automate a key aspect of its production of iPSC derived human cells

...

From Automata Technologies 26 Jan 2023

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced it is supporting a Master’s student at the University of Glasgow (UoG) to undertake a research project on USP30, a DUB implicated in neurodegenerative, renal, and cardiovascular diseases.

From Ubiquigent Limited 23 Jan 2023

Drug Discovery News and Research

Further Reading

MoBIE: New user-friendly, freely available tool for sharing large imaging data sets

Insilico Medicine: IND application for first generative AI-designed drug for COVID-19 approved

Prototype treatment shows great potential in neutralizing snake toxins from multiple species

Mount Sinai researchers illuminate the role of DNA methylation in Alzheimer's disease

"Poisoned" form of a protein could set off events that encourage cancer growth

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

An innovative strategy for on-demand contraception for men

New family of pharmaceutical compounds that target RNA

Gaining insights into human disease biology through CRISPR platforms

New chemical reaction could transform drug production

A high-throughput drug discovery assay for the endoplasmic reticulum aminopeptidase 1

bit.bio partners with Automata to automate a key aspect of its production of iPSC derived human cells

Ubiquigent collaborates with University of Glasgow on translational structural biology to accelerate drug discovery within the (de)ubiquitylation field

Optibrium appoints Steve Yemm as Chief Commercial Officer

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

New technologies reveal cross-cutting breakdowns in Alzheimer’s disease

Molecular motion of “undruggable” proteins reveals drug-binding sites

Optibrium appoints Ian Smith as Chief Technology Officer

Providing structural understanding of the influenza virus

New bioprinting platform to replicate tumors in 3D spheroids

Drug Discovery eBook

Driving Support for Pharmaceutical Testing Through Continuous Innovation

From Memory to Metaplasticity: Unraveling the Brain's Secrets

Revolutionizing Mass Spectrometry: A Deep Dive into Plasmion’s SICRIT® Technology

Latest in Genomics